--- schema_version: "secwatch.filing_event.v1" accession: "0001193125-23-164444" form_type: "8-K" ticker: "SYRE" cik: "0001636282" company_name: "Spyre Therapeutics, Inc." filed_at: "2023-06-09T23:59:59+00:00" generated_at: "2026-06-14T03:55:11.076086+00:00" event_type: "other_material" sentiment: "negative" materiality_score: 0.65 calibrated_materiality_score: 0.65 confidence: "high" source: SEC EDGAR --- # Aeglea shareholders approve reverse stock split; equity incentive plan fails ## Summary - Alison Lawton and Hunter C. Smith elected as Class I directors with 26.8M and 33.8M shares for, respectively. - Ratification of PwC as auditor for FY 2023 approved with 46.9M shares for, 4.1M against. - Reverse stock split (1:10 to 1:25 ratio) approved by 44.1M shares for vs 5.5M against; board to select ratio. - Amendment and restatement of 2016 Equity Incentive Plan defeated: 19.1M for vs 19.3M against (excluding broker non-votes). ## SEC filing metadata - accession: 0001193125-23-164444 - form_type: 8-K - ticker: SYRE - cik: 0001636282 - company_name: Spyre Therapeutics, Inc. - filed_at: 2023-06-09T23:59:59+00:00 - event_type: other_material - sentiment: negative - materiality_score: 0.65 - calibrated_materiality_score: 0.65 - confidence: high - sec_items: 5.07 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000119312523164444/0001193125-23-164444-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000119312523164444/d492050d8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001193125-23-164444 - JSON: https://secwatch.observer/filing/0001193125-23-164444.json - Plain text: https://secwatch.observer/filing/0001193125-23-164444.txt ## Key facts - Shareholder Votes Spyre Therapeutics, Inc. shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-06 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2023-06-06 source text: 2. Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023: Shares For Shares Against Shares Abstaining 46,862,837 4,147,212 147,503 evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000119312523164444/0001193125-23-164444-index.htm - Shareholder Votes Spyre Therapeutics, Inc. shareholders rejected Approval of an amendment and restatement of the Company’s 2016 Equity Incentive Plan at the 2023-06-06 meeting. - Proposal: equity plan - Outcome: failed - Meeting: 2023-06-06 source text: 5. Approval of an amendment and restatement of the Company’s 2016 Equity Incentive Plan: Shares For Shares Against Shares Abstaining Broker Non-Votes 19,133,057 19,349,704 20,035 12,654,756 evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000119312523164444/0001193125-23-164444-index.htm - Shareholder Votes Spyre Therapeutics, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers as disclosed in the proxy statement for the 2023 Annual Meeting of Stockholders at the 2023-06-06 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2023-06-06 source text: 3. Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers as disclosed in the proxy statement for the 2023 Annual Meeting of Stockholders: Shares For Shares Against Shares Abstaining Broker Non-Votes 23,331,453 11,712,005 3,459,338 12,654,756 evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000119312523164444/0001193125-23-164444-index.htm - Shareholder Votes Spyre Therapeutics, Inc. shareholders approved Approval of an amendment to the Company’s restated certificate of incorporation to effect a reverse stock split of the Company’s common stock at a ratio ranging from 1-for-10 shares up to a ratio of 1-for-25 shares, which ratio will be selected by the Company’s board of directors at the 2023-06-06 meeting. - Proposal: reverse split - Outcome: passed - Meeting: 2023-06-06 source text: 4. Approval of an amendment to the Company’s restated certificate of incorporation to effect a reverse stock split of the Company’s common stock at a ratio ranging from 1-for-10 shares up to a ratio of 1-for-25 shares, which ratio will be selected by the Company’s board of directors: Shares For Shares Against Shares Abstaining 44,109,674 5,501,688 1,546,190 evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000119312523164444/0001193125-23-164444-index.htm - Shareholder Votes Spyre Therapeutics, Inc. shareholders approved Election of two Class I directors, Alison Lawton and Hunter C. Smith, M.B.A., each to serve a three-year term at the 2023-06-06 meeting. - Proposal: director election - Outcome: passed - Meeting: 2023-06-06 source text: 1. Election of two Class I directors, Alison Lawton and Hunter C. Smith, M.B.A., each to serve a three-year term, which will expire at the 2026 Annual Meeting of Stockholders and until such time as their respective successors have been duly elected and qualified or until their earlier resignation or removal: Nominees Shares For Shares Withheld Shares Abstaining Broker Non-Votes Alison Lawton 26,794,716 11,708,080 — 12,654,756 Hunter C. Smith, M.B.A. 33,786,894 4,715,902 — 12,654,756 evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000119312523164444/0001193125-23-164444-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.